SANTA MONICA, Calif.--(BUSINESS WIRE)--In a paper published online this week in Science Express (the online version of Science magazine), researchers report that early clinical trials for two compounds, MDV3100 and RD162, show initial promise for patients suffering from an advanced metastatic form of the disease known as castration-resistant prostate cancer. MDV3100, designed to work by antagonizing androgen receptor action and preventing testosterone from fueling tumor growth, reduced PSA levels in 43 percent of patients by more than 50 percent.
